Abstract:Neovascular ocular diseases are among the most common causes of preventable or treatable vision loss. Their management involves lifelong, intravitreal injections of anti-vascular endothelial growth factor (VEGF) therapeutics to inhibit neovascularization, the key pathological step in these diseases. Anti-VEGF products approved for ocular administration are expensive biological agents with limited stability and short half-life. Additionally, their therapeutic advantages are hindered by high treatment resistance, poor patient compliance and the need for frequent, invasive administration. Herein, we used electrospinning to develop a unique, non-porous, PLGA implant for the ocular delivery of siponimod to improve ocular neovascular disease management. Siponimod is an FDA-approved drug for multiple sclerosis with a novel indication as a potential ocular angiogenesis inhibitor. The electrospinning conditions were optimised to produce a microfibrous, PLGA matte that was cut and rolled into the desired implant size. Physical characterisation techniques (Raman, PXRD, DSC and FTIR) indicated siponimod was distributed uniformly within the electrospun fibres as a stabilised, amorphous, solid dispersion with a character modifying drug–polymer interaction. Siponimod dispersion and drug–polymer interactions contributed to the formation of smooth fibres, with reduced porous structures. The apparent reduced porosity, coupled with the drug's hydrophobic dispersion, afforded resistance to water penetration. This led to a slow, controlled, Higuchi-type drug diffusion, with ∼30% of the siponimod load released over 90 days. The released drug inhibited human retinal microvascular endothelial cell migration and did not affect the cells' metabolic activity at different time points. The electrospun implant was physically stable after incubation under stress conditions for three months. This novel siponimod intravitreal implant broadens the therapeutic possibilities for neovascular ocular diseases, representing a potential alternative to biological, anti-VEGF treatments due to lower financial and stability burdens. Additionally, siponimod interaction with PLGA provides a unique opportunity to sustain the drug release from the electrospun fibres, thereby reducing the frequency of intravitreal injection and improving patient adherence.

Silk fibroin nanoparticles for enhanced bio-macromolecule delivery to the retina

Progress in Silk Fibroin Based Composite Scaffold/Hydrogel: Silk Fibroin/PEG Hydrogel for the RPE Regeneration a Promising Biomaterial for Clinical Application

Fabrication and characterization of silk fibroin-coated liposomes for ocular drug delivery

Multifunctional nano-in-micro delivery systems for targeted therapy in fundus neovascularization diseases

Silk Fibroin-Based Nanoparticles for Drug Delivery

Synthesis and characterization of silk fibroin microparticles for intra-articular drug delivery

Preparation and characterization of amphotericin B-loaded silk fibroin nanoparticles-in situ hydrogel composites for topical ophthalmic application

The Systematic Evaluation of Physicochemical and Biological Properties In Vitro and In Vivo for Natural Silk Fibroin Nanoparticles

Silk Fibroin Nanoparticles (SFNs) for nanoencapsulation of bioactive molecules

Silk fibroin as a vehicle for drug delivery applications

Sustaining Intravitreal Residence With L-Arginine Peptide-Conjugated Nanocarriers

Silk Fibroin as a Functional Biomaterial for Drug and Gene Delivery

Development of Nanofibrous Ocular Insert for Retinal Delivery of Fluocinolone Acetonide

Intraocular Fate of Polycaprolactone Nanoparticles Administered Via Intravitreal and Various Periocular Routes: Bioimaging of Integral Nanoparticles Using Environment-Sensitive Fluorophores

Development of puerarin-loaded poly(lactic acid) microspheres for sustained ocular delivery: In vitro / vivo evaluation

Extended siponimod release via low-porosity PLGA fibres: a comprehensive three-month in vitro evaluation for neovascular ocular diseases

A thin film comprising silk peptide and cellulose nanofibrils implanting on the electrospun poly(lactic acid) fibrous scaffolds for biomedical reconstruction

Silk Fibroin Based Drug Delivery Applications: Promises and Challenges

Biosynthesis of insulin-silk fibroin nanoparticles conjugates and in vitro evaluation of a drug delivery system

Developing photothermal-responsive and anti-oxidative silk/dopamine nanoparticles decorated with drugs which were incorporated into silk films as a depot-based drug delivery

Biocompatibility and Safety of Insulin-Loaded Chitosan Nanoparticles/ PLGA-PEG-PLGA Hydrogel (ICNPH) Delivered by Subconjunctival Injection in Rats